Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Novartis Oncology Press Releases ›
10-Dec-2009
Featured Content
Further analysis of BIG 1-98 data supports survival advantage for Novartis drug Femara® over tamoxifen in breast cancer patients
"Selective crossover creates a statistical challenge when analyzing clinical trial results. Statistical methods, such as IPCW, can provide physicians with a more accurate estimate of the clinical benefit of a particular therapy," said Meredith Regan, ScD, Assistant Professor, Department of Medicine, Harvard Medical School and co-author of the BIG 1-98 study IPCW analysis. "By adjusting for the crossover bias in the BIG 1-98 study we have clarified the magnitude of benefit of letrozole compared with tamoxifen on both overall survival and disease-free survival, offering physicians critical information when making treatment decisions for patients."
10-Dec-2009
View Materials Related to Products:
Research
Novartis Oncology is at the forefront of the discovery of new and better therapies. Explore our active pipeline and the many ways in which we strive to improve and extend patient lives.
Disease States
Discover how Novartis addresses particular diseases and conditions to improve health.
Novartis Oncology
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
CONTACT
For information about Novartis Oncology, please contact:
novartis.com
For all other Novartis inquiries, please contact: